NexImmune, Inc. (NEXI)

OTCMKTS · Delayed Price · Currency is USD
0.0002
+0.0001 (100.00%)
At close: Feb 9, 2026
-99.82%
Market Cap 279.00
Revenue (ttm) n/a
Net Income (ttm) -20.62M
Shares Out 1.39M
EPS (ttm) -17.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 507
Average Volume 2,700
Open 0.0002
Previous Close 0.0001
Day's Range 0.0002 - 0.0002
52-Week Range 0.0000 - 2.1700
Beta 5.03
RSI 48.12
Earnings Date n/a

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol NEXI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.